Hepatocellular carcinoma (HCC) is a world leading cause of
cancer-related mortality, and currently no curative treatment for advanced HCC is available.
Glypican-3 (GPC3) is an attractive target for HCC
immunotherapy. This study explored the efficacy of six GPC3-targeted
bispecific antibodies, alone or in combination with chemotherapeutic
drug Irinotecan, for the treatment of HCC. The
bispecific antibodies were constructed using three different structures, knob-into-hole (KH), scFv-scFv-hFc, and scFv-hFc-scFv, where CD3-targeting mAb
OKT3 (scFv) was paired with two representative GPC3 mAbs hYP7 (scFv) and HN3 (VH only) that target different
epitopes. The In vitro cell killing assay revealed that all
bispecific antibodies efficiently killed GPC3 positive
cancer cells, with hYP7-KH, hYP7-OKT3-hFc, and HN3-KH being most potent. In vivo xenograft mouse studies demonstrated that all
bispecific antibodies suppressed
tumor growth similarly, with hYP7-OKT3-hFc performing slightly better. Combination of hYP7-OKT3-hFc with
Irinotecan dramatically improved the efficacy and arrested
tumor growth of HepG2, Hep3B, and G1 in xenograft mice. Our results demonstrated that the cell surface proximal bispecific antibody hYP7-OKT3-hFc was superior in terms of potency and the GPC3-targeted bispecific antibody combined with
Irinotecan was much potent to control HCC growth.